Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRIXNASDAQ:NXGLNASDAQ:PETVNASDAQ:QNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRIXIRIDEX$0.98-1.0%$1.03$0.78▼$2.58$16.45M0.6947,427 shs134,601 shsNXGLNEXGEL$2.18-3.1%$2.66$1.84▼$5.10$16.69M0.6568,390 shs14,584 shsPETVPetVivo$0.80+5.3%$0.61$0.29▼$0.98$19.39M0.7820,434 shs22,782 shsQNRXQuoin Pharmaceuticals$8.90+5.1%$7.41$5.01▼$54.95$5.23M1.39136,409 shs27,522 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRIXIRIDEX-1.03%-2.97%-19.67%-34.88%-62.16%NXGLNEXGEL-3.11%-9.54%-19.26%-34.34%-6.44%PETVPetVivo+5.28%+4.03%+54.17%+35.59%+22.94%QNRXQuoin Pharmaceuticals+5.08%+15.58%+35.67%-20.36%-66.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRIXIRIDEX0.7832 of 5 stars0.04.00.00.02.41.70.0NXGLNEXGEL0.8579 of 5 stars0.05.00.00.00.82.50.0PETVPetVivoN/AN/AN/AN/AN/AN/AN/AN/AQNRXQuoin Pharmaceuticals0.1323 of 5 stars0.03.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRIXIRIDEX 0.00N/AN/AN/ANXGLNEXGEL 0.00N/AN/AN/APETVPetVivo 0.00N/AN/AN/AQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRIXIRIDEX$48.80M0.34N/AN/A$0.59 per share1.66NXGLNEXGEL$10.23M1.63N/AN/A$0.90 per share2.42PETVPetVivo$1.05M18.53N/AN/A($0.03) per share-26.67QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$5.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRIXIRIDEX-$9.57M-$0.43N/A∞N/A-22.79%-192.95%-33.97%8/6/2025 (Estimated)NXGLNEXGEL-$3.16M-$0.45N/A∞N/A-52.60%-71.19%-34.79%N/APETVPetVivo-$10.95M-$0.45N/A∞N/A-902.82%-4,813.07%-281.78%6/26/2025 (Estimated)QNRXQuoin Pharmaceuticals-$8.69M-$48.81N/AN/AN/AN/A-125.60%-64.77%N/ALatest QNRX, NXGL, IRIX, and PETV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IRIXIRIDEX-$0.10-$0.10N/A-$0.10$12.10 million$11.90 million5/13/2025Q1 2025NXGLNEXGEL-$0.10-$0.09+$0.01-$0.09$2.73 million$2.81 million5/13/2025Q1 2025QNRXQuoin Pharmaceuticals-$3.85-$6.50-$2.65-$6.50N/AN/A3/27/2025Q4 2024IRIXIRIDEX-$0.05-$0.05N/A-$0.05$12.80 million$12.70 million3/24/2025Q4 2024NXGLNEXGEL-$0.10-$0.08+$0.02-$0.11$2.99 million$3.04 million3/13/2025Q4 2024QNRXQuoin Pharmaceuticals-$17.50-$12.25+$5.25-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRIXIRIDEXN/AN/AN/AN/AN/ANXGLNEXGELN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRIXIRIDEX0.551.540.85NXGLNEXGEL0.191.510.93PETVPetVivo0.020.420.47QNRXQuoin PharmaceuticalsN/A3.023.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRIXIRIDEX20.10%NXGLNEXGEL2.21%PETVPetVivo24.55%QNRXQuoin Pharmaceuticals8.63%Insider OwnershipCompanyInsider OwnershipIRIXIRIDEX7.30%NXGLNEXGEL20.55%PETVPetVivo10.84%QNRXQuoin Pharmaceuticals3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRIXIRIDEX12016.79 million15.42 millionOptionableNXGLNEXGEL107.66 million5.10 millionNot OptionablePETVPetVivo2024.23 million19.06 millionNot OptionableQNRXQuoin Pharmaceuticals4588,0004.86 millionNot OptionableQNRX, NXGL, IRIX, and PETV HeadlinesRecent News About These CompaniesQuoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical StudyMay 22 at 11:14 AM | manilatimes.netQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton SyndromeMay 20, 2025 | globenewswire.comQuoin reports progress in pediatric skin disorder studyMay 15, 2025 | investing.comQuoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome StudyMay 14, 2025 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial ResultsMay 14, 2025 | manilatimes.netA Peek at Quoin Pharmaceuticals's Future EarningsMay 12, 2025 | benzinga.comQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleMay 1, 2025 | finanznachrichten.deQuoin Pharmaceuticals regains Nasdaq compliance with bid priceMay 1, 2025 | investing.comQuoin Pharmaceuticals regains Nasdaq complianceApril 30, 2025 | msn.comQuoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleApril 30, 2025 | globenewswire.comWhy Quoin Pharmaceuticals, Ltd.’s (QNRX) Stock Is Down 13.50%April 10, 2025 | aaii.comQuoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaignApril 10, 2025 | globenewswire.comQuoin Pharmaceuticals Ltd – ADR trading halted, news pendingApril 9, 2025 | markets.businessinsider.comQuoin Pharmaceuticals announces ADS ratio change to meet Nasdaq requirementsApril 6, 2025 | uk.investing.comQuoin announces additional data from Pediatric Netherton Syndrome studyApril 3, 2025 | markets.businessinsider.comQuoin Reports Clinically Meaningful Whole Body Response to QRX003 in Pediatric Netherton Syndrome; Second Patient Cleared for DosingApril 2, 2025 | reuters.comQuoin Pharmaceuticals Announces Additional Positive ‘Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric PatientApril 2, 2025 | globenewswire.comQuoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin DiseasesMarch 25, 2025 | globenewswire.comQNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26March 18, 2025 | msn.comQuoin Pharmaceuticals reports Q4 EPS (35c) vs ($2.08) last yearMarch 13, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNRX, NXGL, IRIX, and PETV Company DescriptionsIRIDEX NASDAQ:IRIX$0.98 -0.02 (-1.54%) As of 05/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.NEXGEL NASDAQ:NXGL$2.18 -0.07 (-3.11%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.18 0.00 (0.00%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.PetVivo NASDAQ:PETV$0.80 +0.04 (+5.28%) As of 05/23/2025 03:59 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.Quoin Pharmaceuticals NASDAQ:QNRX$8.90 +0.43 (+5.08%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$8.80 -0.10 (-1.11%) As of 05/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
